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Severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) is the 
third zoonotic coronavirus to cross 
the species barrier, infect humans and 
become transmitted between humans1. 
Whereas the two other zoonotic 
coronaviruses, SARS- CoV and Middle 
East respiratory syndrome coronavirus 
(MERS- CoV), could be contained at the 
regional level, SARS- CoV-2 has led to a 
global pandemic known as coronavirus 
disease 2019 (COVID-19). Although 
COVID-19 usually presents as a mild 
respiratory disease, like infections caused 
by the four endemic human coronavirus 
(HCoV-229E, HCoV- NL63, HCoV- OC43 
and HCoV- HKU1), it can occasionally 
lead to severe alveolar inflammation. 
In a large study from China, ~15% of 
SARS- CoV-2- infected patients developed 
shortness of breath, radiological infiltrates 
in the lung and a drop in blood oxygen 
saturation (<93%), and 5% had critical 
illness requiring ventilation2. Although 
such data might slightly overestimate the 
frequency of severe lung involvement, 
because testing for SARS- CoV-2 infection 
is not performed in milder cases and is 
therefore underestimated, COVID-19 
The current COVID-19 pandemic raises 
several interesting research questions, as 
well as clinical challenges in the context 
of rheumatic diseases. In this Perspective 
article, we address some of these points. 
We first consider the musculoskeletal 
symptoms elicited by COVID-19. We then 
describe how the mechanisms of alveolar 
inflammation in COVID-19 share 
similarities with those in rheumatoid 
arthritis (RA), in particular, with respect 
to the pattern of cytokines involved in 
driving the inflammatory process. On the 
basis of this concept, we discuss the potential 
of currently existing cytokine- blocking 
strategies to treat COVID-19, as well as their 
respective impact on the risk of developing 
viral infection. Finally, we critically discuss 
the effect of the COVID-19 pandemic 
on the treatment of patients with rheumatic 
diseases.
Coronavirus and rheumatic symptoms
Musculoskeletal symptoms can develop 
during coronavirus infections, as with 
other respiratory infections. In general, 
viral infections can cause arthritis, but the 
spectrum of symptoms is wide, ranging  
from arthralgia to spurious and chronic  
arthritis6 (Fig. 1). Whereas chronic arthritis 
can be caused by hepatitis C and several 
endemic alphaviruses (such as Chikungunya, 
Ross River, Barmah Forest, Sindbis, O’nyong- 
nyong and Mayaro viruses), self- limited 
arthritis occurs with parvovirus B19, 
rubella or hepatitis B virus6. By contrast, 
coronaviruses do not typically cause  
clinical arthritis but rather arthralgia  
and myalgia7–11. Joint and muscle pain are 
quite rare (occurring in <10% of cases)  
in the endemic coronaviruses, whereas 
arthralgia is reported in 15% of patients 
with COVID-19, and myalgia is even 
more frequent (44%)7,8. Musculoskeletal 
symptoms, however, do not seem to be 
associated with COVID-19 severity8. 
Myalgia is also common in SARS- CoV  
and is found in 49–68% of cases9,10, but 
arthralgia is less frequent (11%). Arthralgia 
and myalgia are also common in patients 
with MERS- CoV (32%)11. However, it needs 
to be considered that these prevalence data 
are based on the background of high doses of 
glucocorticoids (cumulative doses of >1 g). 
Glucocorticoids do not seem to be of benefit 
undoubtedly constitutes a substantial 
risk factor for pulmonary failure. 
Histopathological findings of the lungs of 
deceased patients with COVID-19 showed 
extensive alveolar damage, fibrin deposits, 
widespread infiltration with immune 
cells and thrombosis of small and large 
pulmonary vessels3. Even though the clinical 
picture of severe COVID-19 resembles 
that of acute respiratory distress syndrome 
(ARDS), these lung histopathological 
findings suggest that COVID-19 creates 
a specific form of alveolar disease that 
is different from other forms of ARDS. 
The risk of severe lung disease in the 
context of COVID-19 depends on certain, 
as yet to be determined, susceptibility 
factors of the host. Higher age is one of 
the known risk factors and, as with the 
other zoonotic coronaviruses, the clinical 
course of COVID-19 is more severe in 
older individuals, whereas children and 
adolescents, who typically develop flu- like 
symptoms owing to the four endemic 
coronaviruses, are virtually spared from 
SARS and MERS4. Reports suggest, however, 
that in very rare cases, Kawasaki- like 
disease can occur as a complication of 
COVID-19 (reF.5).
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Abstract | Coronavirus disease 2019 (COVID-19) is an infectious disease, caused 
by severe acute respiratory syndrome coronavirus 2, which predominantly affects 
the lungs and, under certain circumstances, leads to an excessive or uncontrolled 
immune activation and cytokine response in alveolar structures. The pattern of 
pro- inflammatory cytokines induced in COVID-19 has similarities to those targeted 
in the treatment of rheumatoid arthritis. Several clinical studies are underway that 
test the effects of inhibiting IL-6, IL-1β or TNF or targeting cytokine signalling via 
Janus kinase inhibition in the treatment of COVID-19. Despite these similarities, 
COVID-19 and other zoonotic coronavirus- mediated diseases do not induce 
clinical arthritis, suggesting that a local inflammatory niche develops in alveolar 
structures and drives the disease process. COVID-19 constitutes a challenge for 
patients with inflammatory arthritis for several reasons, in particular, the safety of 
immune interventions during the pandemic. Preliminary data, however, do not 
suggest that patients with inflammatory arthritis are at increased risk of COVID-19.
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in SARS or MERS12–14, but they probably 
dampen the musculoskeletal manifestations 
of COVID-19. Overall, COVID-19 seems 
to present with or be complicated by 
mild- to- modest musculoskeletal symptoms, 
which are indistinguishable from those 
associated with other respiratory viruses, 
such as influenza infection. Finally, another 
interesting aspect in the relationship 
between coronaviruses and arthritis is 
that the endemic human coronaviruses 
are associated with an increased risk of 
developing RA. In a large Korean study, 
the authors observed that infections with 
endemic human coronavirus, parainfluenza 
virus and metapneumovirus coincided with 
an increased rate of development of RA15.  
Thus, the COVID-19 pandemic could 
potentially lead to an increase in cases of RA. 
However, to date, there is no report to 
indicate that people develop autoimmune 
inflammatory arthritis, such as RA, after 
being infected by SARS- CoV-2 or any of the 
other six known human coronaviruses.
Alveolar inflammation in COVID-19
Although some data suggest that immune 
cells such as macrophages can be infected  
by SARS viruses, the primary target of  
these viruses is epithelial cells. Infection is  
enabled by cellular expression of angiotensin- 
converting enzyme 2 (ACE2), a carboxy-
peptidase that binds to the spike proteins 
of SARS- CoV and SARS- CoV-2; ACE2 is 
expressed by the epithelium of the mouth, 
tongue and upper airways, thus enabling 
endocytosis of the virus16. In most patients, 
unknown host factors confine the infection 
to these structures, leading to flu- like  
symptoms. ACE2 can be shed from epithelial 
cells by the activity of the metalloproteinase 
ADAM17 (reF.17), which enables ACE2 to  
act as a decoy receptor for SARS- CoV-2, 
potentially preventing viral spreading. The 
most critical step in SARS and MERS inva-
sion is the infection of alveolar type 2 (AT2) 
cells, which also express ACE2. This process 
can lead to the acute alveolar damage  
common to all zoonotic coronaviruses18. 
AT2 cells are important for alveolar regen-
eration after damage, in which setting their 
proliferation depends on IL-1β and TNF 
expressed by resident macrophages and 
other immune cells19.
In some patients with SARS or MERS, 
this inflammatory alveolar niche gets out 
of control (Fig. 2). Age is by far the most 
relevant risk factor for severe COVID-19. 
It is well known that cytokine responses, 
such as IL-6 responses, are increased 
in advanced age20. At the alveolar level, 
transcriptional profiling of AT2 cells from 
the lungs of aged mice has shown that 
these cells have increased transcriptional 
instability, which leads to disrupted cell 
function and more widespread responses21. 
This process might enable the triggering 
of excessive or uncontrolled cytokine 
responses, also referred to as a ‘cytokine 
storm’, in the lungs of patients infected 
with SARS or MERS. In support of this 
concept, circulating serum concentrations 
of most pro- inflammatory effector 
cyto kines, such as TNF, IL-1β, IL-6, IL-8, 
granulocyte colony- stimulating factor 
(G- CSF) and granulocyte–macrophage 
colony- stimulating factor (GM- CSF), as well 
as chemokines, such as CCL2 (also known as 
MCP1), CXCL10 (also known as IP-10) and 
CCL3 (also known as MIP1α), are elevated 
in patients with COVID-19, resembling 
over- activation of innate immunity22. This 
cytokine activation profile illustrates the 
accumulation of an armada of neutrophils 
and bone- marrow- derived macrophages  
in the damaged alveolar structures.
The hierarchical order of cytokines 
involved in COVID-19 is not yet 
known, but mediators that are currently 
therapeutically targeted in RA and in 
autoinflammatory syndromes seem to be of 
central importance23. Initially, epithelial cells 
infected by SARS viruses act as a cytokine 
source, releasing IL-6 and IL-1 as well as 
IL-8 and several other chemokines that can 
activate macrophages, attract neutrophils 
and orchestrate homing of monocytes and 
macrophages to inflammatory sites24. 
For instance, the nucleocapsid protein of 
SARS viruses can activate IL-6 expression 
through the transcription factor NF- κB25. 
After mounting the initial inflammatory 
response to alveolar damage, monocytes and 
macrophages seem to contribute to cytokine 
production. Hence, SARS- CoV stimulates 
macrophages to increase their production of 
certain chemokines (for example, MIP1α), 
as well as IL-6 and TNF26. This effect further 
augments the infiltration and activation of 
neutrophils and macrophages in the alveoli, 
further contributing to tissue destruction.
Infection with SARS viruses is associated 
with peripheral lymphocytopenia, which 
in the case of COVID-19 is present in 
>80% of patients at the time of hospital 
admission and affects predominantly 
CD4+ T cells, including effector memory 
T cells and regulatory T cells22. The 
pathogenesis of COVID-19- associated 
lymphocytopenia is unknown, but it is 
thought that lymphocytes redistribute to 
the lungs. Lessons from previous outbreaks 
of SARS- CoV and MERS- CoV infections 
in fact suggest that these viruses induce 
robust IL-17 production by lymphocytes 
and that IL-17 boosts the pro- inflammatory 
nature of the host anti- viral immune 
response to SARS viruses27,28. In accordance 
with this mechanism, concentrations of 
not only IL-17 but also GM- CSF (another 
important pro- inflammatory mediator 
expressed by T helper 17 (TH17) cells) are 
high in patients with COVID-19 (reFs22,23). 
As IL-17 is involved in the recruitment 
of neutrophils to inflammatory sites, it is 
likely that this cytokine — which, alongside 
TNF, is an important therapeutic target in 
spondyloarthritis and psoriatic arthritis 
— might contribute to the development 
of COVID-19. Notably, IL-17 is not the 
only T cell- derived effector cytokine that is 
elevated in COVID-19 and might contribute 
Infection Arthralgia and/or myalgia Self-limited arthritis Prolonged arthritis
Coronavirusesa
Influenza
Parovirus B19
Rubella
Hepatitis B
Hepatitis C
Alphavirusesb
Frequently reported Sometimes reported Not reported
Fig. 1 | Range of arthritis symptoms associated with infections. Musculoskeletal symptoms that 
can develop during viral infections, including coronavirus infections, range from arthralgia to chronic 
arthritis. aCoronaviruses refer to the zoonotic coronaviruses severe acute respiratory syndrome 
coronavirus (SARS- CoV), SARS- CoV-2 and Middle East respiratory syndrome CoV (MERS- CoV). 
bChikungunya, Ross River, Barmah Forest, Sindbis, O’nyong- nyong and Mayaro viruses.
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to lung inflammation. Concentrations 
of IL-4, IL-9 and IL-13, which are 
associated with type 2 immunity, bronchial 
hypersensitivity and increased mucus 
production, are also high in patients with 
COVID-19 (reF.22). These mediators reflect 
activation of TH2 cells, TH9 cells, eosinophils 
and type 2 innate lymphoid cells in the lungs 
of patients with COVID-19. Although these 
mediators might have a pro- inflammatory 
function in the lungs in COVID-19, several 
previous studies have shown that they act 
differently in the joints and contribute to 
resolution of arthritis29,30.
Arthritis drugs for COVID-19?
SARS- CoV-2, like SARS- CoV and 
MERS- CoV, has the capability to trigger a 
massive immune response associated with 
a cytokine storm, leading to ARDS, which 
can be lethal in the most serious cases of 
COVID-19 (reFs23,31,32). Hence, anti- cytokine 
intervention, which does not increase the 
risk of viral infection and thus might not 
affect viral clearance but would inhibit the 
hyper- inflammatory state in COVID-19, 
might be beneficial33. By contrast, broad 
immunosuppression, especially by targeting 
lymphocyte function, for example, with 
glucocorticoid therapy, could be harmful 
in COVID-19, which itself is associated 
with substantial lymphocytopenia. Indeed, 
none of the current data on SARS- CoV-2, 
SARS- CoV and MERS- CoV supports the 
use of glucocorticoids12–14. Thus, the use 
of anti- cytokine agents in the most critical 
phases of COVID-19 is supported by a 
rationale that overcomes potential concerns 
about dampening the host response to the 
virus. Which pro- inflammatory cytokine 
is most critical to the pathogenesis of 
COVID-19 is currently unknown, although 
IL-6 seems to be pivotal34,35. Indeed, 
the results of a Chinese study36 exploring the 
use of the IL-6 receptor (IL-6R) antagonist 
tocilizumab are encouraging, and several 
trials with IL-6R antagonists (tocilizumab 
and sarilumab) and IL-6 inhibitors 
(sirukumab) have now been initiated37,38. 
IL-1 inhibition also seems to make sense 
in the treatment of COVID-19, as IL-1β is 
produced by AT2 cells upon infection with 
SARS- CoV24 and is an important effector 
cytokine of innate immunity, controlling 
neutrophil and macrophage function. 
Indeed, IL-1β inhibition with high- dose 
anakinra or with canakinumab is currently 
being evaluated as treatment for COVID-19 
(reFs39,40). TNF has been proposed as a 
target for the treatment of SARS- CoV41 and 
more recently for SARS- CoV-2 infection42. 
Preclinical data suggest that TNF inhibition 
mitigates viral pneumonia43, and clinical 
data indicate that patients being treated with 
TNF inhibitors for inflammatory diseases 
do not have a worse outcome of COVID-19 
than those treated with conventional drugs44. 
Currently, a study evaluating the TNF 
inhibitor adalimumab in COVID-19 has 
been registered in the Chinese Clinical Trial 
Registry (ChiCTR2000030089)45.
Beyond the drugs capable of selectively 
blocking cytokines, much attention has been 
paid to drugs that modulate the production 
of more than one cytokine, such as Janus 
kinase (JAK) inhibitors. As mentioned 
above, SARS- CoV-2 enters target cells 
through receptor- mediated endocytosis13. 
Some of the identified regulators of 
clathrin- mediated endocytosis are members 
of the numb- associated kinase family, such 
as AP2- associated protein kinase 1 (AAK1) 
and cyclin G- associated kinase (GAK). 
Inhibition of AAK1 might prevent the virus 
from entering lung cells46, and the JAK 
inhibitor baricitinib is able to effectively 
inhibit AAK1 and GAK47. Moreover, as 
an inhibitor of JAK1 and JAK2, baricitinib 
inhibits IL-6 and GM- CSF, concentrations 
of which are elevated in COVID-19 (reF.22). 
At least five studies with baricitinib, one 
with tofacitinib and one with ruxolitinib 
are ongoing48.
Fig. 2 | alveolar inflammation in CoVID-19. a | In mild disease, the adaptive immune response leads to the clearance of severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) from the lung. b | In severe coronavirus disease 2019 (COVID-19), an excessive or uncontrolled innate immune response leads 
to a cytokine storm and acute respiratory distress syndrome (ARDS). AT1, alveolar type 1; AT2, alveolar type 2; BMM, bone- marrow- derived macrophage; 
GM- CSF, granulocyte–monocyte colony- stimulating factor; IFN, interferon; PAMPs, pathogen- associated molecular patterns; pDC, plasmacytoid dendritic 
cell; PMN, polymorphonuclear granulocyte.
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GM- CSF is a key mediator for macro-
phage and neutrophil attraction from the 
bone marrow to inflamed tissues and is a 
validated target for the treatment of RA. 
GM- CSF thereby represents a link between 
T cell activation and innate immune effec-
tor cells, as TH17 cells are a major source of 
GM- CSF49. As GM- CSF levels are high in 
COVID-19 ((reF.22), studies have been  
initiated of neutralizing antibodies that 
block GM- CSF in COVID-19 (reF.50).
Cytokine inhibition and viruses
Although most of the cytokines induced in 
COVID-19, as well as those being targeted  
in RA and other forms of inflammatory 
arthritis, are important in mounting an 
inflammatory response, they might not be 
essential for controlling virus clearance.  
In support of this concept, therapeutic 
neutra lization of TNF, IL-6 and IL-1β yields 
a moderate increase in bacterial but not viral 
infection. Notably, although the incidence 
of influenza and the risk of developing 
complications from influenza infection is 
2.75- fold higher in patients with RA than 
in indivi duals without RA, no signal related 
to cytokine inhibitor treatment has been 
observed51. In addition, patients with RA 
undergoing treatment with TNF inhibi-
tors achieve a normal immune response to 
influenza vacci nation, further supporting 
the concept that effector cytokines induced 
by SARS- CoV-2 and in RA are critical for 
inflammatory responses but not for viral 
clearance. As a matter of fact, data from 
patients with RA and those with inflam-
matory bowel disease treated with TNF 
inhibitors seem to be reassuring, with no 
increase in the risk of COVID-19 (reFs44,52,53). 
However, further data on the adverse, 
or potentially even beneficial, effects of 
cytokine inhibitors in respiratory infections 
need to be collected, as preclinical data (for 
example, on IL-6) have also suggested that 
cytokines not only have an important role in 
the inflammatory response against viruses 
but are also required to mount a proper 
immune response against the virus54.
In contrast to compounds directed 
against single pro- inflammatory cytokines, 
the use of JAK inhibitors might raise some 
concern, in principle, with respect to viral 
clearance. Type I interferons are among the 
most powerful molecules for preventing 
viral replication. These molecules exert 
their action via JAK–STAT signalling, which 
activates interferon- stimulated genes to 
enable elimination of virus- infected cells. 
Many viruses have developed strategies to 
counteract the effects of type I interferons, 
some of which antagonize the JAK–STAT 
pathway55. Consequently, JAK blockade 
most likely impairs interferon- mediated 
anti- viral responses, which could promote 
rather than inhibit SARS- CoV-2 infection. 
This mechanism explains the increased 
risk of varicella zoster and herpes simplex 
virus infection reported in patients treated 
with JAK inhibitors56. Notably, viral 
infections (including herpes zoster and 
herpes simplex) can account for up to 10% 
of community- acquired and up to 50% of 
ventilator- associated pneumonia cases57. 
Moreover, lymphocytopenia seems to be 
a negative prognostic factor in severely 
affected patients with COVID-19 (reF.58), 
and JAK- inhibitor- induced leukopenia is 
a well- known adverse event. Therefore, 
while awaiting results from ongoing studies, 
a word of caution is warranted before 
suggesting JAK inhibition in this setting59,60.
Beyond studies aimed at identifying 
an effective treatment for COVID-19, 
the availability of a specific vaccine for 
SARS- CoV-2 will certainly offer a possible 
definitive exit from the pandemic. As of 
8 April 2020, the global COVID-19 vaccine 
research and development landscape 
included 115 vaccine candidates, of which 78 
are being actively pursued at the moment61. 
In general, it should be emphasized that, 
despite many discussions about the safety 
and efficacy of vaccination in patients 
receiving immunosuppressive therapy, data 
from large cohorts indicate that vaccines 
might be safer and more effective in this 
setting than previously thought62.
COVID-19 effects on rheumatology
The COVID-19 pandemic is having a 
profound effect on rheumatology practice. 
On the one hand, a large part of the usual 
activity of rheumatology units has been 
absorbed by the growing need to manage 
patients with COVID-19; on the other hand, 
the need to maintain the high standard 
of care required for the treatment of 
rheumatic diseases remains63. The reduction 
in the number of physicians available in 
rheumatology, owing to absence because 
of disease, quarantine or involvement in 
the COVID units, is difficult to reconcile 
with the treat- to- target approach that has 
now become the core of the treatment 
of all chronic inflammatory diseases. In 
addition, ensuring the proper evaluation 
of patients receiving immunomodulatory 
drugs and the timely management of disease 
flares becomes increasingly challenging 
in this context. Rheumatologists should 
reorganize their work by trying to postpone 
all non- urgent visits and weighing the 
potential harm of delaying an in- person visit 
against the potential harm of COVID-19 
infection. We are learning how to make a 
Table 1 | Comparison of mechanistic disease features in CoVID-19 and Ra
Feature CoVID-19 Ra
Disease features
Triggering factor Infectious Autoimmune
Target tissue Alveolar membrane Synovial membrane
Smoking as a risk factor + +
Disease onset Acute Subacute
Disease course Self- limited or lethal Chronic
Effect of glucocorticoids − ++
Contributing cytokines
IL-6 induction ++ +++
TNF induction ++ +++
GM- CSF induction ++ +++
IL-1 induction ++ +
IL-17 induction + +/−
Cellular processes
Resident macrophage defence ++ ++
PMN and macrophage infiltration +++ ++
T cell infiltration ++ ++
Fibrotic response ++ ++
COVID-19, coronavirus disease 2019; GM- CSF, granulocyte–monocyte colony- stimulating factor;  
PMN, polymorphonuclear granulocyte; RA, rheumatoid arthritis. +/−, little or no effect; +, weak positive 
effect; ++, strong positive effect or presence; +++, very strong positive effect or presence; −, no effect or 
negative effect.
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virtue of necessity by unlocking a new era in 
patient management. Indeed, the COVID-19 
pandemic has suddenly disrupted the 
traditional model of health care, both 
for patients with rheumatic diseases and for 
rheumatologists, accelerating the transition 
to remote health care64.
Finally, the widespread use of anti- 
rheumatic drugs in patients with COVID-19 
in areas affected by the pandemic, in a 
fast and sometimes irrationally growing 
market, could endanger supplies of these 
drugs for patients with rheumatic diseases65. 
This challenge is already being faced in 
Europe and the USA regarding the use 
of hydroxychloroquine, chloroquine and 
tocilizumab66. Regulators and manufacturers 
will have to keep this problem in mind to 
avoid unexpected and regrettable disease 
recurrence in patients with rheumatic 
disease owing to suspension of treatment.
Conclusions
The pattern of pro- inflammatory effector 
cytokines in the alveolar membranes  
during severe COVID-19 shares similarities 
with the primary cytokines targeted  
in the treatment of RA (Table 1). Both  
diseases lead to profound inflammation  
of structures that form the inner surfaces of 
the body and induce tissue destruction 
and responses that lead to organ failure. 
COVID-19 is characterized by an excessive 
or uncontrolled host immune response, 
elicited by alveolar epithelial cell damage 
and T cell activation in the lungs that 
triggers exaggerated local production of 
pro- inflammatory effector cytokines and 
leads to the attraction of large numbers 
of neutrophils and macrophages to the 
lungs. Barrier damage, T cell activation, 
effector cytokine production and neutrophil 
influx are also key features of synovitis, 
and some of the mediators are shared 
between COVID-19 and RA. The bulk of 
inflammation and structural damage in 
COVID-19 is limited to the lungs, which are 
progressively destroyed. Furthermore,  
and most likely owing to robust 
IL-6 acti vation, COVID-19 leads to systemic 
acute- phase responses, which are shared 
with RA. Whether cytokine inhibition can 
block this process remains to be determined, 
but a rationale exists for this approach. 
Surprisingly, the original widespread 
concerns about using cytokine inhibitors in 
a potentially life- threating infectious disease 
such as COVID-19 have been balanced 
by the recognition that a pathological 
hyper- inflammatory state is driving the 
pathology and might require therapeutic 
cytokine inhibition. These concepts will  
also affect our advice to patients with 
arthritis about whether to stop or continue 
anti- rheumatic therapy. Given that most  
of these treatments do not increase the risk of 
viral pneumonia, that glucocorticoids, which 
are often used to treat flares, are potentially 
deleterious in COVID-19, and that 
preliminary data from high- risk areas do 
not suggest an increased risk of COVID-19 
in patients with arthritis, anti- rheumatic 
therapy should be continued during the 
pandemic and not be pre- emptively stopped.
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